OQS
TGTX icon

Occudo Quantitative Strategies’s TG Therapeutics TGTX Stock Holding History

Occudo Quantitative Strategies’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,386
Closed -$215K – 889
2025
Q1 		$215K Buy
+5,386
New +$181K 0.03% 547
2022
Q3 		– Sell
-567,576
Closed -$2.41M – 1413
2022
Q2 		$2.41M Buy
+567,576
New +$3.54M 0.2% 137
2021
Q1 		– Sell
-10,158
Closed -$528K – 921
2020
Q4 		$528K Buy
+10,158
New +$343K 0.17% 226

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Occudo Quantitative Strategies's TGTX Position: Q2 2025 in Review

Occudo Quantitative Strategies sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 5,386 shares — an estimated $215K sold.

Occudo Quantitative Strategies first reported a position in TGTX in Q4 2020 and held it in 3 quarters. The position peaked at $2.41M in Q2 2022. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.

  • Occudo Quantitative Strategies reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 5,386 TG Therapeutics shares in Q2 2025, an estimated $215K.
  • Occudo Quantitative Strategies first reported a position in TG Therapeutics in Q4 2020 and held it in 3 quarters.
  • Occudo Quantitative Strategies's TG Therapeutics position peaked at $2.41M in Q2 2022.
  • 356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.